Global Tacrolimus Injection Market - WishTree Insight

Global Tacrolimus Injection Market by Product Type (5mg and Type ||), Application (Adult and Children), End-User (Pharmacy and Hospital), and Regions (APAC, Europe, North America, and LAMEA) - Global Industry Analysis, Share, Growth, Trends, Size, and Forecast 2022 – 2032

The Tacrolimus Injection market size was valued at USD 6.4 billion in 2022 and is expected to surpass USD XX billion by 2032, expanding at a CAGR of 4.7 % during the forecast period, 2022–2032. The market's growth is attributed to the rising number of organ transplants among adult & children’s patients worldwide and the growing demand for the treatment of inflammatory skin diseases.

INTRODUCTION

Tacrolimus injection is a medication used to suppress the immune system. It is typically used to prevent organ rejection in transplant patients and to treat certain autoimmune diseases such as atopic dermatitis and rheumatoid arthritis. Tacrolimus works by blocking the production of certain cytokines, which are proteins that help to regulate the immune system. The injection form allows for a more controlled and consistent delivery of the drug into the bloodstream compared to oral forms. However, it may cause side effects such as kidney problems, high blood pressure, and an increased risk of infection.

Market Trends, Drivers, Restraints, and Opportunities

• Rising awareness regarding immunosuppressive medication and growing organ transplants among the adult population are the key drivers of the market.
• Improvement in the general clinical status of the patient using the drug and rising demand for the treatment of skin-related diseases is driving the market
• Increasing number of pediatric patients suffering from rare and fatal diseases is expected to propel the market.
• The side effects and adverse reactions such as injection bleeding are the key restraining factors hindering the market growth.
• The longer time span of health recovery and the fear of injection are key challenges for market growth.
• Technological advancements and rising R & D investment from major manufacturers providing innovative products are expected to offer lucrative opportunities in the market.

Scope of the Report

Market Segment Insights

The 5 mg segment is projected to register a considerable CAGR

Based on product type, the tacrolimus injection market is divided into 5mg and type ||. The 5 mg segment is expected to expand rapidly during the forecast period owing to rising demand for products and their applications in the treatment of patients. However, the type || segment is anticipated to hold a steady share of the market in the coming years owing to the rising adoption of the product in the treatment.

The adult segment is expected to expand at a rapid pace

Based on application, the tacrolimus injection market is divided into adults and children. The adult segment is expected to expand rapidly during the forecast period owing to the rising number of adults suffering from several fatal diseases and organ disorders. However, the children segment is anticipated to be the fastest-growing segment of the market in the coming years owing to the wide penetration of generic diseases among them.

The hospital segment is projected to register a considerable CAGR

On the basis of end-user, the tacrolimus injection market is segregated into pharmacy and hospital. The hospital segment is projected to register a considerable CAGR during the forecast period owing to the wide availability of advanced medical devices as well as medical staff for treatment. On the other hand, the pharmacy segment is anticipated to account for a major market share during the forecast period due to easy accessibility and cost-effective result.

The North American region holds a major market share

In terms of regions, the tacrolimus injection market is classified as APAC, Europe, North America, and LAMEA. The market of the North American region constitutes a key market share due to the wide adoption of drug treatment in the region. However, the market of the Asia Pacific is anticipated to expand at a rapid pace during the forecast period following a rise in health awareness among patients, which is partially influenced by government policies encouraging the use of the treatment.

Competitive Landscape

Key players competing in the Tacrolimus Injection market are Novartis AG (Switzerland); Astellas Pharma Inc. (Japan); Pfizer Inc. (U.S.); Dr. Reddy’s Laboratories Ltd. (India); Glenmark Pharmaceuticals Ltd. (India); Lupin Limited (India).

FAQs

Mention the market size of the Tacrolimus Injection in 2022.

The market size of the Tacrolimus Injection in 2022 was USD 6.4 billion.

During the forecast period, what is the CAGR of the market?

During the forecast period, the CAGR of the market is expected to be 4.7%.

What are the key drivers of the market?

The market's growth is attributed to the rising number of organ transplants among adult & children’s patients worldwide and the growing demand for the treatment of inflammatory skin diseases.

What segments are covered in the Tacrolimus Injection report?

The segments covered in the report are Product Type (5mg and Type ||), Application (Adult and Children), and End-User (Pharmacy and Hospital).

Mention the key players in the market.

Novartis AG (Switzerland); Astellas Pharma Inc. (Japan); Pfizer Inc. (U.S.); Dr. Reddy’s Laboratories Ltd. (India); Glenmark Pharmaceuticals Ltd. (India); Lupin limited (India)